Lukose Thampy - Michigan State University College of Osteopathic Medicine - Medical Student

Lukose Thampy

Michigan State University College of Osteopathic Medicine

Medical Student

East Lansing, MI | United States

Main Specialties: Hematology & Oncology, Internal Medicine

ORCID logohttps://orcid.org/0000-0002-5332-9366


Top Author

Lukose Thampy - Michigan State University College of Osteopathic Medicine - Medical Student

Lukose Thampy

Introduction

I am a second year medical student interested in utilizing cutting-edge technology (i.e. CAR T cells) to solve complex clinical cases in oncology. Particularly of interest to me are approaches which individualize and optimize anti-cancer therapies.

Primary Affiliation: Michigan State University College of Osteopathic Medicine - East Lansing, MI , United States

Specialties:

Research Interests:


View Lukose Thampy’s Resume / CV

Education

Jun 2018
Washington University School of Medicine in St. Louis
Immunology
Research Assistant
Jun 2016
Georgetown University
M.S.
Physiology
May 2014
University of Michigan-Ann Arbor
B.S.
Biomolecular Science

Experience

May 2018
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock
Research Assistant
Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (Nivolumab) in Participants With Severe Sepsis or Septic Shock.
Dec 2017
Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis
Research Assistant
Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis
Apr 2017
A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-B)
Research Assistant
A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in sepsis patients; IRIS-7B (Immune Reconstitution of Immunosuppressed Sepsis patients). A parallel study will be performed in France to allow a common statistical analysis of the primary end points and analysis for the enrolled patient population.

Publications

2Publications

284Reads

149Profile Views

1PubMed Central Citations

Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration.

PLoS One 2018 26;13(6):e0199497. Epub 2018 Jun 26.

Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199497PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019671PMC
April 2019
173 Reads
1 Citation
3.234 Impact Factor

Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike.

Acute Med Surg 2018 Oct 6;5(4):309-315. Epub 2018 Aug 6.

Departments of Anesthesiology, Medicine, and Surgery Washington University School of Medicine St. Louis Missouri.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ams2.363
Publisher Site
http://dx.doi.org/10.1002/ams2.363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167396PMC
October 2018
111 Reads